Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd.

   Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. is affiliated with Guangzhou Pharmaceutical Holdings Limited, a Fortune Global 500 company. It is a modern pharmaceutical formulation manufacturer integrating drug research and development, production, and sales. The company is located on the picturesque banks of the Pearl River, at No. 808 Binjiang East Road, Haizhu District, Guangzhou, covering an area of approximately 30,000 square meters with an annual output value of about RMB 1 billion. The company adheres to the corporate mission of "Meticulous, Pragmatic, United, Innovative, and Healthy for People," upholds the core values of "Professionalism, Practicality, and Meticulousness," and aims to improve therapeutic efficacy. It continuously drives drug innovation to provide safe and effective medications to patients and promote the development of life and health sciences. Over the years, thanks to its excellent quality and efficacy, the "Xin" trademark has been recognized as a national "Well-Known Trademark." In recent years, the company has been rated as a National High-Tech Enterprise, one of the first batch of National Green Factories, one of the Top 100 Pharmaceutical Industrial Enterprises in China, one of the Top 10 Comprehensive Strength Pharmaceutical Industrial Enterprises in Guangdong Province, a Guangzhou Headquarters Enterprise, and one of the Top 10 Drug Manufacturing Enterprises with the Greatest Coverage in China (Guangdong) 2022.    The company offers a wide variety of products with complete specifications. It currently has more than 200 specifications across multiple dosage forms, including powder injections, small-volume injections, and oral solid preparations. It is one of the largest manufacturers of powder injections and small-volume injections in Guangdong Province and one of the domestic manufacturers with the most complete product coverage for the first, second, third, and fourth generations of cephalosporin powder injections. The company mainly produces and sells two major product categories: the "Antibiotic Series" and the "Cardiovascular and Cerebrovascular Series." Antibiotic series products include Cefuroxime Sodium for Injection, Cefathiamidine for Injection, Clindamycin Phosphate Injection, and Ceftriaxone Sodium for Injection; cardiovascular series products include Candesartan Cilexetil Tablets, Telmisartan Capsules, and Metoprolol Tartrate Sustained-Release Tablets II.    The company places great emphasis on independent intellectual property rights of its products and owns a total of 31 national authorized invention patents. It is recognized as a Guangdong Province Specialized, Refined, Distinctive, and Innovative Small and Medium-sized Enterprise, a Guangdong Province Innovative Small and Medium-sized Enterprise, a Guangdong Province Intellectual Property Demonstration Enterprise, a Guangdong Province Science and Technology Expert Workstation, a Guangdong Province Provincial Enterprise Technology Center, and a Guangdong Province Engineering Technology Research Center for Sterile Preparations, among others.